R&D

Curious for discovery

R&D Strategy

Since its beginnings, the EuroEspes Group been involved with projects for the development of its own R&D&I, the objective being to optimise human health through products and services oriented towards predictive medicine and its preventive applications.

 

The EuroEspes Group continually invests in the research and development of new products. A fundamental area of this being the undertaking of internationally recognised and endorsed scientific studies to demonstrate their beneficial effects on human and animal health.

 

Special mention should be made of the work carried out to date in marine bioprospecting, based on research into active compounds from marine species that are susceptible to development into nutraceuticals. Apart from this, the work carried out by the health biotechnology unit, which carries out intense research focused on diseases of the central nervous system, is also worth highlighting.

 

International recognition is evident through the EuroEspes Group's participation in various national and international collaborative research projects, as well as in scientific results published in prestigious international journals.

 

Likewise, EuroEspes also participates in various entities, such as clusters or associations, whose objective is to respond to sectoral problems, as well as to promote competitiveness and innovation among its members.

 

Among the entities in which EuroEspes actively participates we can highlight:

  • Galician Health Cluster:  the aim of the cluster is to boost business in Galicia, contributing to the economic and social development of the autonomous community, through cooperation between all public and private institutions and companies related to health and healthcare, through the implementation of innovative projects.
  • Life Sciences Technology Ventures Cluster (BIOGA): Bioga's mission is to make the agents and decisions in the biotechnology sector in the Autonomous Community of Galicia more dynamic. The purpose of this is to configure an environment with a far-reaching research system, an active knowledge transfer, and a business network that shapes the economic engine of Galicia and contributes to the welfare of society.
  • Atremorine® - In vivo characterisation of the neuroprotective effect of Atremorine in animal models of Parkinson's disease
  • AntiGan® - Study of the effect of AntiGan in cell and animal models
  • LipoEsar® - Effect on immune system and lipid pathologies
    Development of diagnostic Biopanels
  • Genomics of bone densitometric phenotypes
  • Characterisation of epigenetic risk markers for Alzheimer's disease, vascular and mixed dementias
    Identification of early epigenetic markers for Alzheimer's and Parkinson's diseases.
  • Genotype-Phenotype Correlations in Dementia (Alzheimer's Disease, Vascular Dementia)
  • Novel Therapeutic Strategies in Alzheimer's disease
  • Genomics and Pharmacogenomics of ADHD
  • Brain Mapping: Genotype-Phenotype Correlations
  • Digital Optical Topography: Genotype-Phenotype Correlations
  • Development of a Nutrigenomics Card for diet personalisation
  • Histamine function in CNS Disorders
  • Robotisation of Industrial Freeze-Drying Systems for the Manufacture of Nutraceutical Products
  • Mitochondrial and nuclear genetic risk in Vascular Dementia, Alzheimer’s, and Parkinson’s disease
  • Effect of the bioproduct Celergen on 30 healthy women: assessment of biochemical parameters
  • Preclinical characterisation of the effects of the nutraceutical CabyMar on muscle power and energy performance.
  • Food Sensitivity: Frequency of Problem Foods in the Spanish Population

Development of pharmacogenetic profiles of therapeutic utility in pathologies of the central nervous system.

  • TransBioModel: Development of cellular and murine models with biomedical application
  • Transgenesis: Development of transgenic products
  • Development Biochips for primary screening (Pharmacogenetic Screening)
  • On-line clinical pharmacogenetics platform: EuroPharmaGenics (Phase II)
  • Blue Butterfly
  • BrainRex® - Neurodegenerative Protection and Neuropathologies
  • EB101 Alzheimer's disease vaccine development (Phase II)
  • Neurogenomic profile characterization of novel 3xTg mouse model of AD
  • Study of the pharmacogenomic characterisation of the Spanish population.
  • Development of the UCJC-Card Pharmacogenetics Card for the personalisation of pharmacological treatment.
  • Intelligent Pharmacogenetic Card for the personalisation of Pharmacological Treatment
  • Influence of the APOE-TOMM40 locus on Alzheimer's Disease phenotype and Pharmacogenomics
  • In vivo and in vitro characterisation of the effect of Pigoline in animal models of cerebral vascular occlusion and neurodegeneration.
  • Development of new pharmacogenomic characterisation tools for the personalisation of treatments for prevalent pathologies.
  • Electrophysiological and Genomic Diagnostics Project: Genomic Characterisation of Cartographic Patterns in the Diagnosis of Central Nervous System Diseases.
  • Exploring Marine Resources for Bioactive Compounds: From Discovery to Sustainable Production and Industrial Applications
  • Exploring Marine Resources for Bioactive Compounds: From Discovery to Sustainable Production and Industrial Applications
  • Online platform for clinical pharmacogenetics: EuroPharmaGenics (Phase I)
  • Study of the effects of Cerebrolysin (CBL) on serum BDNF levels in patients with probable Alzheimer's disease: Double-blind comparison with Aricept (Donepezil) and a combination therapy
  • Development of new products with lipoproteins of marine origin for the SOS Group.
  • Non-invasive prenatal genetic diagnosis: identification and isolation of foetal cells in maternal blood for DNA analysis
  • Studies on the immunoregulatory activity of FR-91. (Georgian Alternative Medicine S.L. GEAMED)
  • Pharmacogenetic pattern of CYP2C9 and VKORC1 in the Spanish population.
  • Genetic susceptibility for stroke risk
  • Alzheimer's Vaccine Project
  • Setting up an R&D laboratory for the identification of genetic markers associated with Alzheimer's disease.
  • Efficacy experiments using an in vivo rat amyloid-beta-injection model (Solvay study number S330.5.027)
  • Development of new products with lipoproteins of marine origin
  • Effects of Cerebrolysin on quantitative brain bioelectrical activity and cognitive performance in patients with probable Alzheimer's Disease: Double-blind comparison with Aricept (Donepezil) and a combination therapy 
  • Comparison with Aricept (Donepezil) and a combination therapy
  • Obtaining new products with bioactive properties. Qualia Lacteos S.L.
  • Provision of laboratory equipment for the company EuroEspes Biotecnología SA for the research of a non-invasive prenatal genetic diagnosis system. (Sample Bank)
  • Detection of Age-Related Memory Impairment (AMD) and Mild Cognitive Impairment (MCI) in a representative sample of the area of A Coruña: Evaluation of biological and neuropsychological risk factors for Senile Dementia (SD).
  • Study of the effects of Cerebrolysin (CBL) on the circulating levels of free IGF-I and TNF-alpha in Alzheimer's disease. Correlations with cognitive and clinical parameters. Preliminary testing of Abeta40 and Abeta42
  • Study of the effects of Cerebrolysin (CBL) on the circulating levels of free Abeta-42 and Abeta-40 in Alzheimer's disease: Correlations with cognitive and clinical parameters
  • Study of the effect on lipid levels of chickpeas supplemented with lipoproteins of marine origin.
  • Study of the effect on lipid levels of beans supplemented with lipoproteins of marine origin.
  • Plasma and CSF levels of AB-40 and AB-42 in Alzheimer's disease and associated diseases: potential correlation between IGF-I and TNF-alpha levels.
  • Serum and CSF levels of IGF-I and TNF-alpha in Alzheimer's disease and associated diseases: functional correlations and potential changes in circulating receptor concentrations.
  • Alzheimer's disease treatment targeting truncated AB40/42 by active immunisation
  • Study of the potential effects of Cerebrolysin (CBL) on the circulating levels of insulin growth factor-binding proteins (IGFBP-1 and IGFBP-3) and on soluble tumour necrosis factor receptors (sTNF RI and RII) in Alzheimer's disease: Correlations with cognitive and clinical parameters.
  • Experimental testing of the properties of the new products developed for Alimentos Naturales, S.A.
  • Validation study of the ETG-4000 system, identification of stimuli capable of generating specific activation in brain regions of interest, inspection mapping in volunteers, identification of specific signals associated with APOE genotypes in Alzheimer's disease and vascular dementia.
  • Pharmacogenetics and pharmacogenomics characterisation of multifactorial treatments in Alzheimer's disease
  • Ebiosea Project
  • Identification of genomic susceptibility profiles for Alzheimer's and vascular dementias and development of a high-throughput genotyping platform for diagnosis and pharmacogenomics research (PROFIT).
  • Comparative genotypic study of CYP2D6 between healthy Spanish population and those with dementia.
  •     Comparative study of CYP2C19 genotypes between people whose ethnicity is Spanish Caucasian and Colombian mixed-race
  • Study for the determination of the APOE genotype in a sample of 120 subjects for the detection of people with age-related memory impairment, mild cognitive impairment and senile dementia in the population of Granada.
  • Randomised, double-blind clinical study to compare the safety and efficacy of Cerebrolysin, Aricept (Donepezil) and a combination therapy in patients with probable Alzheimer's disease.
  • Biodefensor Biological Effects Analysis
  • Study of the potential effects of Cerebrolysin on circulating levels of growth factors and inflammation in Alzheimer's disease patients: correlations with cognitive and clinical parameters.
  • 26-week, open-label, randomised, multicentre, double-blind, placebo-controlled clinical study compared to a parallel group on the efficacy of 10 and 15 mg twice daily of Phenserine in patients with probable Alzheimer's disease.
  • Development of DNA Microarrays for diagnosis and pharmacogenomic study of diseases of the nervous system.
  • Development of DNA microchips for diagnosis and pharmacogenomic research into diseases of the central nervous system. Torres Quevedo Project
  • CYP2D6 gene study in Alzheimer's disease
  • Study of the potential anti-apoptotic and neuroprotective effects of LipoEsar in an animal model of beta-amyloid-induced neurodegeneration.
  • Study of the anti-atheromatous effect of LipoEsar (E-SAR-94010) in patients with hyperlipidaemia.
  • Pharmacogenomic study of the lipid-lowering activity of LipoEsar associated with APOE genotype in patients with hyperlipidaemia.
  • Potential neuroimmunotrophic and neuroprotective effects of MMZ-1-025 in an animal model of beta-amyloid and LPS-induced neurodegeneration
  • Study of the effects of desoxypeganine on behaviour in AF64A rats.
  • Study of the lipid-lowering and anti-arteriosclerotic activity of the marine lipoprotein compound E-SAR-94010 (LipoEsar).
  • Project for the realisation of a Pilot Plant to produce lipoprotein extracts from marine fish.
  • Cacabelos, R. Acetylcholinesterase inhibitors as a factor of hope in the treatment of Alzheimer's disease. The Elderly in the Year 2000. Old are the Rags. Auditorium of the Hospitals of the University of Coimbra. Portuguese Association of Gerontopsychiatry. Coimbra, 20-22 January (2000).
  • Cacabelos, R. Genetics of Alzheimer's disease. Workshop University of Coimbra. 22 January (2000).
  • Cacabelos, R. Advances in the aetiology of dementias. VII National Congress. Colombian Association of Biological Psychiatry. Pereira, Colombia, 18-19 March (2000).
  • Cacabelos, R. Pharmacogenetics of dementias. VII National Congress. Colombian Association of Biological Psychiatry. Pereira, Colombia, 18-19 March (2000).
  • Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Álvarez, X.A. Genotype-specific apoptosis and therapeutic response in Alzheimer disease: Implications for drug design and clinical trials. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 41 (2000).
  • Álvarez, X.A., Fernández-Novoa, L., De Olano, M., Sampedro, C., Lombardi, V., Windisch, M., Cacabelos, R. Cerebrolysin exerts neuroimmunotrophic and neuroprotective effects in an animal model of hippocampal neurodegeneration. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 197 (2000).
  • Álvarez, X.A., Lombardi, V.R.M., Corzo, L., Pérez, P., Pichel, V., Laredo, M., Hernández, A., Freixeiro, F., Sampedro, C., Lorenzo, R., Alcaraz, M., Windisch, M., Cacabelos, R. Oral Cerebrolysin potentiates brain alpha activity and improves memory in elderly humans. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 197 (2000).
  • Álvarez, X.A., Sampedro, C., Lozano, R., Secades, J., Cacabelos, R. Citicoline protects hippocampal neurons against apoptosis induced by brain -amyloid deposits plus cerebral hypoperfusion in rats. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 198 (2000).
  • Álvarez, X.A., Pichel, V., Pérez, P., Laredo, M., Corzo, L., Zas, R., Fernández-Novoa, L., Sempere, J.M., Díaz, J., Cacabelos, R. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: Effects on cognition, brain electrical activity and cerebral hemodynamics. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 198 (2000).
  • Cacabelos, R., Álvarez, X.A., Laredo, M., Couceiro, V., Anido, R., Pérez, P., Pichel, V., Corzo, L., Zas, R., Alcaraz, M., García, M., Rodríguez, S., Freixeiro, F., Figueroa, J., Hernández, M.A., Lombardi, V., Fernández-Novoa, L. Cognitive performance in dementia patients during a 4-year follow-up with a neuroprotective multifactorial treatment: Comparative effects for prevention in subjects at risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 201 (2000).
  • Cacabelos, R., Moreno, A., Caamaño, J.M., López, S., Pérez, P., Pichel, V., Laredo, M., Couceiro, V., Anido, R., Corzo, L., Zas, R., Alcaraz, M., Rodríguez, S., Hernández, M.A., Álvarez, X.A., Lombardi, V., Fernández-Novoa, L. Cognitive function and brain atrophy in dementia: A psychomorphometric correlation analysis. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 202 (2000).
  • de Olano, M., Fernández-Novoa, L., Mesa, M.D., Corzo, L., Cacabelos, R. Different allele frequency distribution in angiotensin-converting enzyme I/D polymorphism and angiotensinogen M235T polymorphism in dementia. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 205 (2000).
  • Fernández-Novoa, L., De Olano, M., Mesa, M.D., Cacabelos, R. Alpha-2 macroglobulin V1000I and insertion-deletion polymorphisms in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 208 (2000).
  • Fernández-Novoa, L., de Olano, M., Mesa, M.D., Corzo, L., Lombardi, V., Álvarez, X.A., Cacabelos, R. Identification of two novel mutations in the amyloid precursor protein (APP) gene. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 208 (2000).
  • Lombardi, V.R.M., Fernández-Novoa, L., Sampedro, C., De Olano, M., Álvarez, X.A., Cacabelos, R. Overexpression of FAS/CD95 in spontaneous and induced apoptosis in lymphocytes from Alzheimer's disease patients. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, April 5-8, pp. 217 (2000).
  • Cacabelos, R. Review of research in geriatric psychiatry. American Society of Hispanic Psychiatry and University of Chicago of Illinois at Chicago. Hispanic American Day at the APA Annual Meeting. May 13 (2000).
  • Álvarez, X.A., Lombardi, V.R.M., Fernández-Novoa, L., García, M., Sampedro, C., Cagiao, A., Windisch, M., Moessler, H., Cacabelos, R. Cerebrolysin reduces microglia activation in vivo and in vitro: A potential neuroprotection mechanism. Neuroinflammation in Alzheimer's Disease. A Neurobiology of Aging Conference. Washington DC, 7-8 July, pp. 2.06 (2000).
  • Lombardi, V.R.M., Álvarez, X.A., Fernández-Novoa, L., García, M., Sampedro, C., de Olano, M., Cacabelos, R. Regulation of brain immunity: A central role played by -amyloid and IL-1 in microglial cells. Neuroinflammation in Alzheimer's Disease. A Neurobiology of Aging Conference. Washington DC, 7-8 July, pp. 2.07 (2000).
  • Lombardi, V.R.M., Álvarez, X.A., Fernández-Novoa, L., de Olano, M., Corzo, L., Sampedro, C., Cacabelos, R. One year "plateau-phase" in microglial cell cultures. Neuroinflammation in Alzheimer's Disease. A Neurobiology of Aging Conference. Washington DC, 7-8 July, pp. 2.08 (2000).
  • Cacabelos, R., Sampedro, C., Álvarez, X.A. Citicoline exerts antiapoptotic effects in an animal model of hippocampal neurodegeneration. World Alzheimer Congress 2000. Washington DC, July 9-13, pp. S87 (2000).
  • Lombardi, V., Cacabelos, R., Pérez, P., Laredo, M., Moessler, H., Hernández, A., Windisch, M., Álvarez, X.A. Cerebrolysin improves memory performance and the brain bioelectrical activity pattern in elderly humans. World Alzheimer Congress 2000. Washington DC, July 9-13, pp. S157 (2000).
  • Álvarez, X.A., Pichel, V., Pérez, P., Laredo, M., Corzo, L., Zas, R., Fernández-Novoa, L., Cacabelos, R. Dose-dependent effects of Anapsos in senile dementia patients: A double-blind, randomized, placebo-controlled study. World Alzheimer Congress 2000. Washington DC, July 9-13, pp. S218 (2000).
  • Mesa, M.D., Fernández-Novoa, L., de Olano, M., Cacabelos, R. Allele frequency of alpha-2 macroglobulin V1000I and insertion-deletion polymorphism in Alzheimer's disease patients. World Alzheimer Congress 2000. Washington DC, July 9-13, pp. S250 (2000).
  • Fernández-Novoa, L., Mesa, M.D., Corzo, L., de Olano, M., Cacabelos, R. Two novel mutations in the amyloid precursor protein (APP) gene. World Alzheimer Congress 2000. Washington DC, July 9-13, pp. S250 (2000).
  • De Olano, M., Fernández-Novoa, L., Mesa, M.D., Corzo, L., Cacabelos, R. Angiotensin-converting enzyme I/D polymorphism and ansiotensinogen M235T polymorphism in dementia: A genetic study. World Alzheimer Congress 2000. Washington DC, July 9-13, pp. S250 (2000).
  • Lombardi, V.R.M., Álvarez, X.A., Fernández-Novoa, L., de Olano, M., Perea, L., Daniele, D., Cacabelos, R. Regulation of MHC class-I and class-II expression and neuronal death by citicoline. IV European Meeting on Glial Cell Function in Health and Disease. Barcelona, 24-27 May, pp. 100 (2000).
  • Lombardi, V.R.M., Álvarez, X.A., Sampedro, C., Miguel-Hidalgo, J.J., Quack, G., Cacabelos, R. Modulation of A(1-40)-induced neurodegeneration in the CA1 subfield by memantine. IV European Meeting on Glial Cell Function in Health and Disease. Barcelona, 24-27 May, pp. 100 (2000).
  • Lombardi, V.R.M., Álvarez, X.A., Sampedro, C., Cacabelos, R. Cerebrolysin-regulated microglial function through the modulation of proinflammatory cytokines. IV European Meeting on Glial Cell Function in Health and Disease. Barcelona, 24-27 May, pp. 107 (2000).
  • Álvarez, X.A., de Olano, M., Sampedro, C., Lombardi, V., Moessler, H., Windisch, M., Cacabelos, R. Cerebrolysin protects against neurodegeneration induced by -amyloid in rats. XXIInd CINP Congress, Brussels, 9-13 July, pp. S359 (2000).
  • Álvarez, X.A., Lombardi, V.R.M., Corzo, L., Zas, R., Pérez, P., Pichel, V., Laredo, M., Hernández, A., Freixeiro, F., Sampedro, C., Lorenzo, R., Alcaraz, M., Moessler, H., Windisch, M., Cacabelos, R. Oral Cerebrolysin accelerates the brain bioelectrical activity pattern and enhances memory performance in elderly humans. XXIInd CINP Congress, Brussels, 9-13 July, pp. S359 (2000).
  • Álvarez, X.A., Sampedro, C., Lozano, R., Secades, J., Cacabelos, R. Citicoline protects neurons against apoptosis induced by deposits of -amyloid into the hippocampus plus cerebral hypoperfusion in rats. XXIInd CINP Congress, Brussels, 9-13 July, pp. S359 (2000).
  • Cacabelos, R., Álvarez, X.A., Fernández-Novoa, L., Mesa, M., Olano, M., Laredo, M., Pichel, V., Pérez, P., Corzo, L., Lombardi, V. Genotype-related therapeutic response in Alzheimer's disease: A pharmacogenomic approach. VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR-Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Florence, 15-20 July, 2000. British J. Clin. Pharmacol., pp. 31 (2000).
  • Álvarez, X.A., Lombardi, V.R.M., Fernández-Novoa, L., García, M., Sampedro, C., Cagiao, A., Windisch, M., Moessler, H., Cacabelos, R. Cerebrolysin reduces microglia activation in vivo and in vitro. VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR-Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Florence, 15-20 July, 2000. British J. Clin. Pharmacol., pp. 177 (2000).
  • Álvarez, X.A., Lombardi, V., Corzo, L., Pérez, P., Pichel, V., Laredo, M., Hernández, A., Freixeiro, F., Sampedro, C., Lorenzo, R., Alcaraz, M., Windisch, M., Moessler, H., Cacabelos, R. Cerebrolysin improves memory and induces brain bioelectrical activation in elderly humans after a single oral administration. VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR-Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Florence, 15-20 July, 2000. British J. Clin. Pharmacol., pp. 177 (2000).
  • Álvarez, X.A., Pichel, V., Pérez, P., Laredo, M., Corzo, D., Zas, R., Fernández-Novoa, L., Sempere, J.M., Díaz, J., Cacabelos, R. Effects of anapsos on cognition, brain bioelectrical activity and cerebral hemodynamics in senile dementia: A double-blind, randomized, placebo-controlled study. VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR-Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Florence, 15-20 July, 2000. British J. Clin. Pharmacol., pp. 125 (2000).
  • Álvarez, X.A., Mouzo, R., Pichel, V., Pérez, P., Laredo, M., Fernández-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J.J., Lozano, R., Cacabelos, R. Effects of citicoline on cognitive performance, brain bioelectrical activity and cerebral perfusion in APOE-genotyped Alzheimer's disease patients. VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR-Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Florence, 15-20 July, 2000. British J. Clin. Pharmacol., pp. 176 (2000).
  • Álvarez, X.A., Sampedro, C., Lozano, R., Secades, J., Cacabelos, R. Neuroprotective and antiapoptotic effects of citicoline in rats with hippocampal degeneration induced by -amyloid and hypoperfusion. VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR-Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Florence, 15-20 July, 2000. British J. Clin. Pharmacol., pp. 176 (2000).
  • Álvarez, X.A., Miguel-Hidalgo, J.J., Quack, G., Cacabelos, R. Memantine protects against neuronal degeneration induced by A(1-40) in the CA1 subfield of the rat hippocampus. VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR-Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Florence, 15-20 July, 2000. British J. Clin. Pharmacol., pp. 176 (2000).
  • Fernández-Novoa, L., de Olano, M., Mesa, M.D., Cacabelos, R. Alpha-2 macroglobulin polymorphism in Alzheimer's disease. Eighth World Congress of Psychiatric Genetics. Versailles, 27-31 August, pp. 522 (2000).
  • de Olano, M., Fernández-Novoa, L., Mesa, M.D., Corzo, L., Cacabelos, R. Association between ACE I/D and APOE polymorphisms in different kinds of dementia. Eighth World Congress of Psychiatric Genetics. Versailles, 27-31 August, pp. 522 (2000).
  • Fernández-Novoa, L., de Olano, M., Mesa, M.D., Corzo, L., Cacabelos, R. Identification of two novel mutations in the amyloid precursor protein (APP) gene. Eighth World Congress of Psychiatric Genetics. Versailles, 27-31 August, pp. 522 (2000).
  • Cacabelos, R., Álvarez, X.A., Fernández-Novoa, L., Mesa, M.D., Olano, M., Laredo, M., Pichel, V., Pérez, P., Corzo, L., Lombardi, V. A pharmacogenomic approach to Alzheimer disease treatment. Eighth World Congress of Psychiatric Genetics. Versailles, 27-31 August, pp. 541 (2000).
  • Cacabelos, R. Hypertension and dementia. VII Congress of the Galician Society of Arterial Hypertension. Sada, La Coruña, Sept. 8-9 (2000).
  • Corzo, L., Álvarez, X.A., Zas, R., Rodríguez, S., Pérez, P., Cacabelos, R. Blood pressure, lipid and glucose levels in patients with senile dementia: Correlation study. VII Congress of the Galician Society of Arterial Hypertension. Sada, La Coruña, Sept. 8-9, pp. 596 (2000).
  • Álvarez, X.A., Mouzo, R., Pichel, V., Laredo, M., Pérez, P., Couceiro, V., Corzo, L., Zas, R., Varela, M., Sampedro, C., Fernández-Novoa, L., Mesa, M.D., De Olano, M., Cacabelos, R. Blood pressure and apolipoprotein E (APOE) genotype in senile dementia. VII Congress of the Galician Society of Arterial Hypertension. Sada, La Coruña, Sept. 8-9, pp. 600 (2000).
  • Fernández-Novoa, L., Corzo, L., de Olano, M., Cacabelos, R. Study of ACE and AGT gene polymorphisms in dementia and arterial hypertension. VII Congress of the Galician Society of Arterial Hypertension. Sada, La Coruña, Sept. 8-9, pp. 600 (2000).
  • Cacabelos, R. Update in Alzheimer therapeutics. Pfizer CNS Symposium. Dementia hoje... o olhar no futuro. Funchal, Madeira, Portugal. 23 Sept. (2000).
  • Cacabelos, R. Genetics of schizophrenia and psychotic syndrome. XVIII Venezuelan Congress of Psychiatry "Dr. Mauro Villegas". Psychiatry of the New Millennium. Hotel Radisson Plaza Eurobuilding, Caracas, 18-21 October 2000.
  • Cacabelos, R. Pharmacogenetics of Alzheimer's disease. XVIII Venezuelan Congress of Psychiatry "Dr. Mauro Villegas". Psychiatry of the New Millennium. Hotel Radisson Plaza Eurobuilding, Caracas, 18-21 October 2000.
  • Cacabelos, R. Genomics: Diagnostic and therapeutic implications. International Symposium. Towards a Gerontological Society. University of Oviedo and Ramón Areces Foundation, Oviedo, 21-22 November, 2000.
  • Study of the effects of milk consumption on calcium metabolism, immunological parameters and cognitive performance in people of different ages.
  • Study of the potential neuroprotective and neuroimmunotrophic effects of cerebrolysin in an animal model of beta-amyloid-induced neurodegeneration. Part One
  • Study of the effects of CDP-choline on apoptosis in a model of combined neurodegeneration induced by beta-amyloid and hypoperfusion.
  • Randomised, prospective, multicentre, parallel, double-blind, multi-centre study to evaluate the efficacy and safety of Efonidipine HCl compared to Amlodipine in patients with mild to moderate hypertension.
  • Study of APOE, PS1 and PS2 genotype on serum levels of Total Cholesterol, HDL-Cholesterol, LDL-Cholesterol, triglycerides, apolipoprotein E (ApoE), beta-amyloid and oxidative status in subjects with vascular dementia and Alzheimer's disease versus controls.
  • Applied Biotechnology Programme 1. Use of the marine extracts E-SAR, E-JUR and E-CAB in pigs
  • Socio-demographic Study of the Autonomous Community of Castile-Leon
  • Study of the neuroprotective effects of memantine in a model of neuronal degeneration and behavioural disorder after injection of beta-amyloid into the hippocampus.
  • Clinical study on the efficacy and safety of the fixed combination perindopril/indapamide oral in 400 non-insulin-dependent diabetic hypertensive patients with albuminuria, for 52 weeks. Equivalence study, versus enalapril, double-blind, randomised, controlled, in two parallel groups.
  • Study of the effect of citicoline on glia and neuron cultures
  • Study of the effects of cerebrolysin on cultured rat microglia and astrocytes in vitro.
  • Development of an animal feeding programme with immunoprotective properties for pig colonies. First phase
  • Detection of caspase mRNA in animal models of neurodegeneration and in the brains of Alzheimer's disease patients.
  • Genetic kit for the molecular characterisation of Alzheimer's disease: Genetic risk markers
  • Study of the effect of S12024-2 on cultured glial and endothelial cells
  • Study of the effect of S9977-2 on cultured glial and endothelial cells
  • Study of the efficacy of S-20499 (2 to 20 mg/day) in generalised anxiety. Double-blind controlled study versus placebo and versus diazepam.
  • Evaluation of the efficacy and safety of 3 doses of S-20098 (l, 10, 50 mg) administered orally once daily for 24 weeks in 400 outpatients with Alzheimer's dementia and sleep/wakefulness disorders. Double-blind controlled study versus placebo.
  • Study of the effects of two doses of Anapsos (360, 720 mg/day) on cognitive function, cerebral bioelectrical activity and cerebral haemodynamics in oral and chronic administration (28 days) in patients with medium-moderate senile dementia. Double-blind, placebo-controlled study
  • Study of the neuroprotective and neuroimmunotrophic effects of Anapsos in an animal model of neurodegeneration.
  • Study of the effects of two doses of CDP-choline (1000, 1500 mg/day) on cognitive function, cerebral bioelectrical activity and cerebral haemodynamics in oral and chronic administration (84 days) in patients with medium/moderate Alzheimer's disease. Double-blind, placebo-controlled study
  • Effects of CDP-choline on bromazepam treatment-induced memory and motor performance deficits in rats
  • Study of the neuroprotective and neuronal cytoskeleton-stabilising properties of CDP-choline in the brain of injured rats. 
  • Studies of memory and behaviour in the same animals
  • Effects of CDP-choline on cognitive performance in memory-impaired subjects/patients without senile dementia
  • Clinical trial for the use of Tacrine (CI 970) in the treatment of mild-moderate dementia in patients with probable Alzheimer's disease.
  • Genetic kit for the molecular diagnosis of Alzheimer's disease: Risk markers
  • Potential neuroprotective effects of S-12024-2 in rats with brain p-amyloid implants
  • Potential neuroprotective effects of S-9977-2 in rats with brain p-amyloid implants
  • Genetic kit for the molecular diagnosis of Alzheimer's disease: Risk markers
  • Study of the effects of Anapsos on longevity in mice
  • Study of the effects of Anapsos on cell survival and differentiation in neuronal transplants in the brain.
  • Time- and dose-dependent study of the effects of S-9977-2 on brain vasopressin levels in rats.
  • Study of the cognitive effects of 2 doses of the drug S-12024 (100, 300 mg/day) in oral and chronic administration (12 weeks) in 300 outpatients with medium-moderate Alzheimer's dementia (AD). Multicentre study versus placebo
  • Time- and dose-dependent effects of S-12024 on cerebral vasopressin levels in rats
  • Study of the effects of S-9977 vs Tacrine on psychomotor activity and passive avoidance learning in rats.
  • Study of the effect of CDP-choline on cerebral P-amyloid protein deposits in the AD-EE-p/A4 animal model of Alzheimer's disease.
  • Neuro-immuno-regulatory and anti-amyloidogenic activity of CDP-choline (Somazine)
  • Study of the time- and dose-dependent effects (at 90 and 120 minutes) of S-12024 on brain vasopressin levels in rats.
  • Study of the time and dose-dependent effects (at 90 and 120 minutes) of S-9977 on brain vasopressin levels in rats.
  • Joint-Venture between ASAC Pharmaceutical International and EuroEspes on basic and clinical research of Anapsos
  • Study of the effect of pharmacologically active plant extracts of Iberoamerican plants on behaviour, neuroimmune function, superoxide dismutase activity and brain amyloid deposition in an animal model of Alzheimer's disease: neurotrophic, immuno-regulatory, anti-oxidative and anti-amyloidogenic activity.
  • Madaus GB Project: Preliminary Study
  • Madaus GB Project
  • Study of the effect of GB on psychomotor activity, passive avoidance learning and neuroimmune function in a pharmacological model of cognitive impairment in rats.
  • Study of the effects of GB on psychomotor activity, passive avoidance learning and neuroimmune function in rats with lesions of the nucleus basalis magnocellularis of Meynert.
  • Preliminary study of the behavioural and neuroimmune effects of silibinin
  • Research study on the effects of pharmacologically active plant extracts of Iberoamerican plants on behaviour in intact animals and in rats with lesions of the basal magnocellular nucleus of Meynert, as well as in vivo neuroimmunomodulation studies with cytokine and histamine titration.
  • Study of the effects of CDP-choline on neuroimmune function in patients with senile dementia
    Study of the activity of 3 doses of S-12024 (0, 100, 300 mg/day) on cognitive functions, cerebral cartography and cerebral blood flow in repeated oral administration (28 days) in 45 outpatients with dementia of Alzheimer type.
  • Project Andromachus/P-L
  • Study of the effects of Polypodium Leucotomos on psychomotor activity, passive avoidance learning, and neuroimmune function in rats.
  • Study of the effects of Polypodium Leucotomos on psychomotor activity, passive avoidance learning and neuroimmune function in rats with lesions of the nucleus basalis magnocellularis of Meynert.
  • Study of the time- and dose-dependent effects of S-9977 on central and peripheral histamine levels.
  • Protocol for screening of the immunomodulatory potential of plant extracts A21, A22, A23, S2, S3 and AN
  • Clinical study of the effect of Anapsos on cognitive function in Alzheimer's disease patients
  • Study of the effect of Anapsos on neuroimmune function in patients with Alzheimer's disease.
  • Study of the effects of S-12024 on neuroimmune function in patients with Alzheimer's disease.
  • Study of the effects of Anapsos on neuroimmune function, behaviour, memory and learning in rats
    Study of the influence of CDP-choline on brain bioelectrical activity and neurovascular haemodynamics in Alzheimer's disease, and multi-infarct dementia.
  • Study of the effects of S-9977 on plasma and brain interleukin-1p, learning and behaviour in normal rats and in an animal model of Alzheimer's disease.
  • Study of the efficacy of Betahistine on cognitive functions in an animal model of Alzheimer's disease.
X

Leave us your contact information and we will contact you.

Leave us your contact information and we will contact you.